BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Subscribe To Our Newsletter & Stay Updated